Last reviewed · How we verify

ISOCONAZOLE

Phase 2 active Small molecule

ISOCONAZOLE is a isoconazole drug. It is currently in Phase 2 development.

ISOCONAZOLE works by inhibiting the enzyme steroid 17-alpha-hydroxylase/17,20 lyase, which is involved in the production of steroids and other hormones.

ISOCONAZOLE is a small molecule drug that targets the enzyme steroid 17-alpha-hydroxylase/17,20 lyase. It is classified as an isoconazole and is used to treat various fungal infections. However, its commercial status and approved indications are unknown. As a result, its half-life, bioavailability, and generic manufacturers are also not available. Further research is needed to determine its safety and efficacy.

Likelihood of approval
17.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Anti-infectives pathway favourability +2.0pp
    Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameISOCONAZOLE
Drug classisoconazole
TargetIndoleamine 2,3-dioxygenase 1, Steroid 17-alpha-hydroxylase/17,20 lyase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

Think of it like a traffic cop: ISOCONAZOLE blocks the enzyme that helps make certain hormones, which can help fight fungal infections. This is a complex process, but essentially, it helps reduce the production of hormones that can contribute to fungal growth.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ISOCONAZOLE

What is ISOCONAZOLE?

ISOCONAZOLE is a isoconazole drug.

How does ISOCONAZOLE work?

ISOCONAZOLE works by inhibiting the enzyme steroid 17-alpha-hydroxylase/17,20 lyase, which is involved in the production of steroids and other hormones.

What drug class is ISOCONAZOLE in?

ISOCONAZOLE belongs to the isoconazole class. See all isoconazole drugs at /class/isoconazole.

What development phase is ISOCONAZOLE in?

ISOCONAZOLE is in Phase 2.

What does ISOCONAZOLE target?

ISOCONAZOLE targets Indoleamine 2,3-dioxygenase 1, Steroid 17-alpha-hydroxylase/17,20 lyase and is a isoconazole.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing